Tvardi Therapeutics, Inc. Share Price

Tvardi Therapeutics, Inc. Share Price

NASDAQ: TVRD | Micro Cap
$0.79
-$0.08 (-8.68%) Last updated on 31 Oct, 2026 | 01:29 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Tvardi Therapeutics, Inc. Stock Performance

Open
$0.87
Prev. Close
$0.87
Circuit Range
N/A
Day Range
$0.79 - $0.87
Year Range
$0.79 - $5.66
Volume
1,156
Average Traded
$0.82

Tvardi Therapeutics, Inc. Share Price Today

As of 31 October 2026, Tvardi Therapeutics, Inc.'s share price is $0.79. The stock opened at $0.87, compared to its previous close of $0.87. During today's trading session, Tvardi Therapeutics, Inc.'s share price traded between $0.79 and $0.87, with an average price of $0.83. Over the past 52 weeks, the stock has recorded a high of $5.66 and a low of $0.79. In terms of performance, Tvardi Therapeutics, Inc.'s share price has declined by 74.67% over the last six months and is down 83.01% on a year-on-year basis.

Tvardi Therapeutics, Inc. Share Price Chart

Line chart of the Tvardi Therapeutics, Inc. price trend over the selected period. The price fell overall, ranging from 0.79 to 0.87, ending at 0.79.
$0.79$0.87
L
Show Current Price
H

Tvardi Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$5.88M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-1.95
Revenue (TTM)
$0.00
Return On Equity (TTM)
-310.94%
Profit Margin
N/A
Debt to Equity
0.00
Quarterly Earnings Growth YoY
-16.82%

Tvardi Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$5.53-$7.28-$6.80-$6.46
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A-31.65%6.59%5.00%

Tvardi Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2025
Revenue$0.00
Net Profit-$18.21
Net Profit MarginN/A
Income ChangeN/A

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.

Tvardi Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$1.22
$0.81
-34.76%
Sep 2026
$1.81
$1.24
-32.24%
Aug 2026
$2.06
$1.83
-13.27%
Jul 2026
$1.86
$2.11
+9.61%
Jun 2026
$3.33
$1.93
-43.22%
May 2026
$3.13
$3.39
+8.31%
Apr 2026
$3.11
$3.13
-1.57%
Mar 2026
$4.11
$3.18
-20.10%
Feb 2026
$3.93
$3.98
+0.76%
Jan 2026
$4.26
$3.95
-8.35%
Dec 2025
$4.08
$4.31
+4.48%
Nov 2025
$4.63
$4.13
-11.58%

TVRD Share Price FAQs